European Commission
European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients
The approval makes Merck's PD-1 inhibitor available to European TNBC patients whose tumors express PD-L1 with a combined positive score of at least 10.
EU IVDR Implementation Woes Could Severely Limit Cancer Companion Test, Precision Therapy Access
Premium
The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.
CHMP Recommends Merck's Keytruda Plus Chemo for PD-L1-Positve TNBC
The committee recommended the combo for PD-L1-positive advanced cancers based on data from the Phase III KEYNOTE-355 trial.
Bristol Myers CAR T-Cell Therapy Abecma Approved for Multiple Myeloma in Europe
The company is also seeking to expand its manufacturing capabilities for Abecma with plans to add a facility in the EU.
Merck's Keytruda Plus Chemo Approved in Europe for Certain Gastroesophageal Cancers
The European Commission approved the combination as first-line treatment for PD-L1-expressing advanced esophageal cancer or HER2-negative GEJ cancer.